Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024.
加利福尼亞庫比蒂諾，2024年9月4日（環球新聞社） - Reviva Pharmaceuticals Holdings, Inc.（納斯達克：RVPH）（「Reviva」或「公司」），一家處於後期階段的藥品公司，開發旨在解決中樞神經系統（CNS）、炎症和心臟代謝疾病領域未滿醫療需求的療法，今天宣佈，Reviva的創始人、總裁兼首席執行官拉克仔林納蘭·巴特（Laxminarayan Bhat）博士將出席2024年9月9日至11日舉行的H.C. Wainwright第26屆全球投資大會。
H.C. Wainwright 26th Annual Global Investment Conference
Format: Corporate update
Date/Time: Pre-recorded presentation available on-demand Monday, September 9, at 7:00 a.m. ET
Webcast Link: Click Here
H.C. Wainwright第26屆全球投資者會議
格式：企業更新
日期/時間：預錄製演示將於東部時間9月9日星期一上午7點提供隨時觀看的服務。
網絡直播鏈接：點擊這裏
Management will also be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact your H.C. Wainwright sales representative to register for the conference.
管理層還將參加在整個活動期間舉行的虛擬一對一會議。要安排與管理層的會議，請聯繫您的H.C. Wainwright銷售代表註冊參加會議。
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Reviva是一家後期生物製藥公司，致力於爲代表醫學需求和對社會、患者及其家人造成負擔的疾病開發、發現和尋求商業化的下一代治療方案。 Reviva目前的產品管道集中於中樞神經、呼吸和代謝類疾病。Reviva的產品管道目前包括兩種藥物候選，即Brilaroxazine（RP5063）和RP1208。兩者均是公司內部自行發現的新型化學實體。 Reviva已在美國，歐洲和其他幾個國家獲得了Brilaroxazine和RP1208的組成專利權。
Reviva是一家晚期生物製藥公司，致力於發現、開發並尋求商業化對於社會、患者及其家庭構成醫療需求和負擔的下一代治療方法。Reviva的當前管線專注於中樞神經系統(CNS)、炎症和心血管代謝疾病。Reviva目前的管線包括兩個藥物候選，即布瑞拉洛昔(RP5063)和RP1208。兩者均是公司在內部發現的新化學物質。Reviva已在美國、歐洲和其他幾個國家獲得了布瑞拉洛昔和RP1208的構成專利權。
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
公司聯繫人:
Reviva Pharmaceuticals Holdings，Inc.
Laxminarayan Bhat，博士
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
投資者關係聯繫人：
LifeSci Advisors，LLC
Bruce Mackle
bmackle@lifesciadvisors.com
Media Contact:
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783
媒體聯繫人：
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783
譯文內容由第三人軟體翻譯。